| 4 min read
Psychedelic acquisitions, clinical trial updates, and more led the news this week.
| 5 min read
Aurion Biotech's manufacturing approach to unmodified allogeneic corneal endothelial cells offers a set of hard-won lessons for a cell therapy field still working out how to get from proof-of-concept to broad patient access.
| 3 min read
A new platform combines engineered viral vectors with the brain's glymphatic system to improve gene delivery to glial cells implicated in multiple neurological disorders.News
| 3 min read
KCL-286 repaired neuronal DNA damage and reduced neuroinflammation in mice, with prior Phase 1 safety data potentially accelerating its path to Alzheimer's trials.
| 3 min read
Pediatric brain cancer is extremely challenging to treat. Results from a Phase 1 cell therapy trial revealed encouraging long-term survival rates.
| 4 min read
Data on a new oral pill for Duchenne muscular dystrophy, a miss for a heart drug, a $10B acquisition of Crinetics, and more led the news this week.
| 3 min read
Researchers showed that an oral medication can activate worn-out T cells.
| 4 min read
7-methylxanthine is being reformulated into a sustained-release oral therapy aimed at improving long-term control of axial elongation in childhood myopia.
| 5 min read
The Synthetic Molecule Process Innovation Phorum brings together major pharma companies, regulators, and CDMOs to build consensus on pressing challenges in small molecule manufacturing.
| 2 min read
For the first time, researchers imaged a human protein essential to the RNA interference process and found ways to design better siRNA drugs.
| 3 min read
Patient advocates warn that political momentum to reduce animal testing is outpacing the scientific validation of alternative methods.
| 5 min read
Therapeutic cancer vaccines are being reengineered to deliver stronger immune activation and longer-lasting protection against disease recurrence.
